Orthodontics After Cancer Treatment UK

How radiotherapy affects the jaws and teeth

Radiotherapy to the head and neck region is the cancer treatment most likely to affect orthodontic prospects. The primary concern is osteoradionecrosis (ORN) — a serious condition in which irradiated bone loses its ability to heal after injury or surgical interference. The mandible (lower jaw) is more susceptible than the maxilla because of its relatively poor blood supply. ORN can be triggered by procedures that disturb bone — including tooth extractions, implant placement, and potentially orthodontic forces applied to the alveolar bone in a heavily irradiated field. The risk is proportional to the radiation dose received; doses above 60 Gray to the jaw carry a substantially higher ORN risk. Even at lower doses, the bone's remodelling capacity — which underpins tooth movement in orthodontics — is permanently reduced. This means tooth movement in an irradiated field tends to be slower, less predictable, and carries a higher risk of root resorption and bone loss.

Xerostomia and its effect on braces and aligners

Xerostomia — clinically significant dry mouth — is a common and often permanent consequence of radiotherapy to the salivary glands, which are frequently in the treatment field for head and neck cancers. Saliva plays a critical protective role: it neutralises acids, remineralises enamel, and mechanically clears food debris and bacteria. Without adequate saliva, patients wearing fixed braces are at dramatically elevated risk of demineralisation (white spot lesions) and rampant caries. Even with impeccable hygiene, the risk is substantially higher than in a patient with normal salivary flow. Clear aligners are generally preferred over fixed braces in this group when orthodontic treatment is undertaken, as they can be removed for enhanced cleaning. However, aligner retention and comfort may also be affected by the altered oral environment. Salivary substitutes, fluoride varnish at every appointment, high-concentration fluoride toothpaste (5,000 ppm), and chlorhexidine rinses are typically recommended throughout treatment.

Bisphosphonate use during cancer treatment

Some cancer patients receive bisphosphonates — either orally or intravenously — as part of their management, particularly for bone metastases or to reduce fracture risk in multiple myeloma and breast cancer. Intravenous bisphosphonates (such as zoledronic acid and pamidronate) carry a significant risk of medication-related osteonecrosis of the jaw (MRONJ), which is triggered or worsened by any procedure that disturbs the jaw bone. The risk is considerably higher than with oral bisphosphonate use. Orthodontic extractions in patients who have received intravenous bisphosphonates require careful pre-treatment risk assessment in liaison with the prescribing oncologist or haematologist. The risk of MRONJ does not resolve when bisphosphonates are stopped; it persists because these drugs remain in bone for years. Extraction-based orthodontic treatment plans should be avoided or replaced with non-extraction alternatives wherever possible in this patient group.

Chemotherapy and orthodontic treatment

Chemotherapy affects orthodontics primarily through immune suppression, delayed wound healing, and — in childhood patients — potential effects on dental development. During active chemotherapy, orthodontic treatment is typically paused or not initiated because the immune suppression increases the risk of oral infections (including from bacteria displaced during bracket placement or adjustment), mucosal breakdown, and delayed healing. Mucositis — painful inflammation of the oral lining — is a frequent side effect that makes wearing braces extremely uncomfortable. Once chemotherapy is completed and blood counts have recovered to safe levels, these concerns largely resolve, and orthodontic treatment can generally be resumed or commenced with appropriate monitoring. Childhood patients who received chemotherapy or radiotherapy at a young age may have dental developmental anomalies including hypodontia (missing teeth), microdontia (small teeth), shortened roots, and premature root closure, all of which need to be accounted for in treatment planning.

Recommended waiting periods

There is no single universally agreed waiting period, but UK clinical practice typically follows guidance indicating that elective orthodontic treatment — particularly any treatment involving extractions — should be deferred for a minimum of two years following completion of head and neck radiotherapy. This reflects the period of highest ORN risk immediately post-radiotherapy and allows time to assess long-term soft tissue and bone healing. Some specialists recommend waiting three to five years, particularly where high doses were received to the mandible. Following chemotherapy alone (without radiotherapy to the jaws), the waiting period is shorter — typically until full haematological recovery is confirmed, which is usually three to six months post-completion for standard regimens. All decisions should be made with input from the treating oncology team, not the orthodontist alone. In many cases, a hyperbaric oxygen (HBO) therapy course may be recommended before and after any planned surgical procedures (including extractions) in a previously irradiated jaw; your oncologist can advise on this.

Liaison between oncology team and orthodontist

Any orthodontist treating a patient who has had cancer — particularly head and neck cancer — should obtain a full written summary from the oncology team before commencing treatment. This should include the type of treatment received, radiation fields and doses, any bisphosphonate history, current disease status, and current medications. This is not a formality; it is essential clinical information that directly affects treatment planning decisions. Patients should proactively request this information and bring it to their orthodontic consultation. The orthodontist may in turn wish to seek advice from a maxillofacial surgeon before embarking on any extraction-based plan in a previously irradiated case. A multidisciplinary approach is best practice and reduces avoidable harm.

Enhanced hygiene protocols and realistic expectations

Patients with a cancer history require a higher level of orthodontic monitoring than standard patients. Appointments should be more frequent to assess oral hygiene, check for early signs of demineralisation, and ensure there are no signs of soft tissue breakdown. Dietary advice, fluoride supplementation, and saliva management must be actively managed throughout. Patients and their families should be counselled that tooth movement in irradiated bone may be slower and less predictable, that treatment may take longer than in a standard patient, and that the risk of root resorption is higher. These are not reasons to avoid treatment — well-planned orthodontics can significantly improve quality of life after cancer — but realistic expectations from the outset prevent disappointment and support informed consent.

Useful related pages

This guide is for general information only. It is not a diagnosis, treatment plan, or substitute for advice from a registered dentist or orthodontist.